| Document |
Document Title |
|
WO/2005/023772A1 |
The invention relates to malonamide derivatives of formula (I), wherein: R1 is one of the following groups (Formulae a), b), c), d)); R2 is lower alkyl, lower alkinyl, -(CH2)n-O-lower alkyl, -(CH2)n-S-lower alkyl, -(CH2)n-CN, -(CR'R')n-C...
|
|
WO/2005/021487A1 |
This invention relates to a novel class of compounds, represented by the formula (I) below, wherein the meanings of R1, R2, R3 and R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors...
|
|
WO/2005/019180A1 |
The present invention provides a 7-chloro-6-(2,2,2-trifluoroethylamino)-2,3,4,5-tetrahydro-1H
-benzo[d]azepine of formula (I): or a pharmaceutically acceptable salt thereof, and its use as a selective 5-HT2c agonist for the treatment of ...
|
|
WO/2005/019179A2 |
The present invention provides processes and intermediates for the preparation of 3-benzazepines and salts thereof which can be useful as serotonin (5-HT) receptor agonists for the treatment of , for example, central nervous system disor...
|
|
WO/2005/016891A1 |
The invention provides compounds of formula (I): wherein A and B represent the groups -(CH2)m- and -(CH2)n- respectively; R1 represents hydrogen or C1-6alkyl; R2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC1-6alkyl, trif...
|
|
WO/2005/014578A1 |
The invention provides compounds of formula (I): wherein A and B represent the groups -(CH 2) m- and -(CH 2) n- respectively; R1 represents hydrogen or C1-6alkyl; R2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC 1-6 alkyl...
|
|
WO/2005/014574A1 |
This invention relates to certain substituted lactam compounds of the formula (I), particularly caprolactam compounds, which are useful for the treatment of cancer.
|
|
WO/2005/012266A1 |
The present invention relates to new D3 and D2 dopamine receptor subtype preferring ligands of formula (I): wherein R1 and R2 represent independently a substituent selected from hydrogen, alkyl, aryl, cycloalkyl, aroyl, or R1 and R2 may ...
|
|
WO/2005/009972A2 |
The present invention relates to an improved process for preparation of highly pure benazepril of Formula I, wherein R is hydrogen or pharmacologically acceptable salt thereof by completely eliminating the impurity of 7-bromo analogue of...
|
|
WO/2005/007630A2 |
This invention is directed to compounds of the formula (I): and their pharmaceutically acceptable salts, wherein R1, R2, R3 and Z are as defined herein; intermediates for the synthesis of such compounds, pharmaceutical compositions conta...
|
|
WO/2005/005392A1 |
Compounds of the formula (I), and pharmaceutically acceptable salts thereof, are found to be antagonists of SNS sodium channels. They are therefore useful as analgesic and neuroprotective agents wherein: X is -N- or -CH-; n is from 0 to 3.
|
|
WO/2005/003096A1 |
The present invention relates to certain 1-substituted-2,3,4,5-tetrahydro-3-benzazepine derivatives of Formula (I), that are modulators of the 5HT2C receptor. Accordingly, compounds of the present invention are useful for the prophylaxis...
|
|
WO/2005/000819A1 |
Novel spirobenzoazepine compounds, novel processes for the preparation of nonpeptide substituted spirobenzoazepine dervatives, and novel processes for the preparation of intermediates in the preparation of such derivatives. Novel interme...
|
|
WO/2004/113288A1 |
Method for making caprolactam from 6-aminocapronitrile that contains greater than 500 ppm tetrahydroazepine and its derivatives (THA) in which ammonia and water are removed from crude caprolactam in a single separation step and then THA ...
|
|
WO/2004/110986A1 |
A compound which functions to inhibit capsaicin receptor VR1 activation and is useful as a therapeutic agent for, e.g., various pains including inflammatory pain and neurogenic pain, migraine, cluster headache, and bladder diseases inclu...
|
|
WO/2004/110983A2 |
Compounds of general structure (I), wherein the central benzene ring may be substituted in the meta- or para-position; -A is an optionally substituted hydroxyl, alkoxyl, hydroxylamine, alkoxylamine or amine radical; -W is an N- and C...
|
|
WO/2004/099153A1 |
A high-yielding method for racemisation of (S)-(+)- and (R)-(-)-10, 11- dihydro-l0-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide and a useful intermediate, 10-chloro-10, 11 dihydro-5H-dibenz/b,f/azepine-5-carboxamide (VII) are disclosed....
|
|
WO/2004/096795A2 |
The invention is directed to compounds of formulae (I), (II) and (III), wherein A, R1, R2, R3, R4, X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that...
|
|
WO/2004/096775A1 |
A novel 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative represented by the following formula (I) or a pharmaceutically acceptable salt of the derivative. They are useful as a therapeutic or preventive agent for night pollakis...
|
|
WO/2004/094387A1 |
Disclosed herein is an antioxidant that is an alkylated iminodibenzyl of the general formula: (I) wherein: R1, R2, R3, and R4 are independently selected from the group consisting of hydrogen, alkyl moieties, and alkenyl moieties; and R5,...
|
|
WO/2004/093796A2 |
Lactam derivatives of the general formula (I), are disclosed. Pharmaceutical compositions containing the compounds and methods for their use are also disclosed.
|
|
WO/2004/093817A2 |
Compounds that interact with the CXCR4 receptor are described. The compounds are useful in treating for Example, HIV infection and inflammatory conditions such as rheumatoid arthritis, as well as asthma or cancer, and are useful in metho...
|
|
WO/2004/089890A2 |
Disclosed is a new process and intermediates for preparing benzazepines of Formula wherein R1 and R2 are as defined herein.
|
|
WO1995018619A9 |
Certain compounds within formula (I) are inhibitors of platelet aggregation wherein A<1> is NH or CH<2>; R is H, C1-6alkyl, benzyl or a carboxy protecting group; R<3> is C1-6alkyl, Ar- C0-6alkyl, C1-6cycloalkyl C0-6alkyl, or Het C0-6alky...
|
|
WO/2004/084898A1 |
The present invention relates to a benzenesulfonamide derivative of formula (I), which is useful as an active ingredient of pharmaceutical preparations. The benzenesulfonamide derivatives of the present invention have CCR3 (CC type chemo...
|
|
WO/2004/080983A1 |
This invention relates to novel compounds having formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit secretase and thereby inhibit the production of amyloid ß protein, thereby acti...
|
|
WO/2004/080932A2 |
A method for recovering hexamethylene diamine (HMD) from a mixture (18) comprising HMD, 6-aminocapronitrile (ACN) tetrahydroazepine (THA), and ADN comprising: (a) introducing the mixture into a distillation column (20) capable of separat...
|
|
WO/2004/080969A1 |
The invention provides compounds of the formula: (I) and pharmaceutically acceptable salts or prodrugs thereof, wherein m, p, q, r, A, E, X, Y, R1, R4, R5, R6, R7, R8, R9 and are as defined herein. The invention also provides methods for...
|
|
WO/2004/073716A1 |
A method for treating severe heart failure, comprising administering to a patient an effective amount of a benzazepine compound (1): wherein R¿1? is H or halogen, R¿2? is OH, or -NR¿5?R¿6? (R¿5? and R¿6? are H or lower alkyl, R¿3?...
|
|
WO/2004/071445A2 |
A chemical genus of 2-(aminomethyl)arylamides, which are useful as analgesics, is disclosed. The genus is represented by the Formula I: a representative example is:
|
|
WO/2004/071460A2 |
The present application describes modulators of MCP-1 of formula (I): [chemical structure] or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asth...
|
|
WO/2004/069826A1 |
The invention relates to malonamide derivatives of formula (IA) or (IB) and to pharmaceutically suitable acid addition salts thereof. The compounds are &gammad -secretase inhibitors and the related compounds may be useful in the treatmen...
|
|
WO/2004/069275A1 |
It is intended to provide ophthalmic drugs comprising, as the active ingredient, a compound acting on a calcium handling protein to thereby control intracellular calcium concentration or the seed of intracellular calcium concentration ch...
|
|
WO/2004/067522A1 |
Novel azaphenylalanine derivatives of the formula I and pharmaceutically acceptable salts thereof are described wherein the substituents have the meanings as specified in the description. The compounds are useful as anticoagulants.
|
|
WO/2004/067675A2 |
A blue electroluminescent material based on a binaphtyl compound of the general formula (I). Particular embodiments having the general formula have good solubilities in common organic solvents, resist crystallization and can be sublimed ...
|
|
WO/2004/065351A1 |
Compounds of the formula (I) provide pharmacological agents which lower intracellular glucocorticoid concentrations in mammals, in particular, intracellular cortisol levels in humans. Therefore, the compounds of the instant invention imp...
|
|
WO/2004/060376A1 |
The present invention relates to a class of compounds represented by the Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula (I), and methods of selectively inhibitin...
|
|
WO/2004/058757A1 |
Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds of Formula (I): are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein n is an integer equal to zero, 1 or 2, and R1, R3, R4, R12 and R14 are d...
|
|
WO/2004/058756A1 |
Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds of Formula (A): are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein n is an integer equal to zero, 1, 2 or 3, and R1, R3, R4, R12, R14, R16,...
|
|
WO/2004/056182A1 |
Use of compounds of formula (I): wherein X is S, O, S=O, SO2, NRa, or CRbRc;R1,R2 are halogen, OH, SH, NH2, CN, NO2, alkyl, alkoxy, alkylamino, dialkylamino, alkylthio, alkenyl, alkenyloxy, alkenylamino, alkenylthio, alkynyl, alkynyloxy,...
|
|
WO/2004/056369A1 |
The present invention relates to benzazepine derivatives of formula ( I ) wherein: R1 represents -C3-7 cycloalkyl optionally substituted by C1-3 alkyl; having pharmacological activity, processes for their preparation, to compositions con...
|
|
WO/2004/052847A2 |
The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula...
|
|
WO/2004/045536A2 |
A method for modifying at least one non-ester-containing parent compound, and the compounds produced using such method, which compounds are deployed to temporarily incapacitate at least one subject are disclosed. The modified compounds a...
|
|
WO/2004/045533A2 |
A method and compositions for treating persistent pulmonary hypertension in human newborns that deploys an intravenous infusion of a modified drug formed by adding one or more of a predetermined chemical arrangement to an efficacious par...
|
|
WO/2004/043939A1 |
Disclosed is a compound having the formula (I) pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and so...
|
|
WO/2004/042351A2 |
The present invention is directed to compounds of the formula (I): (wherein R¿1?, R¿2?, R¿3?, R¿4?, R¿5?, R¿6?, W, X, Z, m and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, thes...
|
|
WO/2004/037788A1 |
The present invention relates to novel bicyclic benzamide derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric dis...
|
|
WO/2004/035544A1 |
The present invention relates to novel benzazepine derivatives of formula (I) having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychia...
|
|
WO/2004/035521A1 |
Compounds of Formula (1), wherein R1 is hydrogen; C1-C18alkyl; trifluoromethyl; C3-C8cycloalkyl; phenyl-C1-C5alkyl; phenyl-C1-C5alkoxy; mono- or di-N-C1-C5alkylamino-C1-C5alkyl; amino-di-N-C1-C5alkylamino-C1-C5alkyl; C1-C5alkoxy-C1-C5alk...
|
|
WO2004014391B1 |
The present invention relates to the use of carbamazepine derivatives in treating tinnitus.
|
